Get started
Author

Viola K. DeTemple

Observed names: DeTemple, V., DeTemple, V. K., V.K. DeTemple, Viola De Temple, Viola DeTemple, Viola K DeTemple
Observed institutions: Medizinische Hochschule Hannover, Essen University Hospital, Johannes Wesling Klinikum Minden, Deutsches Konsortium für Translationale Krebsforschung, University of Duisburg-Essen, Ruhr University Bochum
ORCID: 0000-0001-6246-8862
Observed ORCID: 0000-0001-6246-8862
OpenAlex ID: A5036714509
S2k Guideline – Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – Update 2022
2023 · Jürgen C. Becker, Ambros J. Beer, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 25
PDF
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
2021 · Anne Zaremba, Rafaela Kramer, et al. · Frontiers in Oncology · 25
PDF
A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition
2025 · Nina Flatt, Antje Walter, et al. · Frontiers in Immunology · 13
PDF
Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes
2016 · Viola DeTemple, Imke Satzger, et al. · Experimental Dermatology · 13
S2k‐Leitlinie – Merkelzellkarzinom – Update 2022
2023 · Jürgen C. Becker, Ambros J. Beer, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 9
PDF
Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients
2022 · Viola K. DeTemple, Jessica C. Hassel, et al. · Cancers · 9
PDF
Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization
2024 · Viola K. DeTemple, Antje Walter, et al. · Archives of Dermatological Research · 5
Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma
2025 · Viola K. DeTemple, Martin Kaatz, et al. · European Journal of Cancer · 3
Short- and long-term immunosuppressive effects of melanoma influence the prognostic value of the sentinel lymph node status
2024 · Viola K. DeTemple, Cathrin Ritter, et al. · European Journal of Cancer · 1
Immune and tumor-intrinsic signatures are associated with resistance and response to PD-1 blockade in cutaneous squamous cell carcinoma
2026 · Viola K. DeTemple, Maximilian Beikirch, et al. · Cancer Immunology Immunotherapy
PDF
Alcian blue‐positive stromal phenotype in basal cell carcinoma is associated with progression on first‐line hedgehog inhibitors
2026 · Viola K DeTemple, Rudolf Stadler, et al. · The Journal of Pathology Clinical Research
Gene Signatures as Predictive Biomarkers for PD-1 Blockade in Cutaneous Squamous Cell Carcinoma
2026 · K. Schaper-Gerhardt, V.K. DeTemple, et al. · EJC Skin Cancer
Predictive biomarkers for advanced basal cell carcinoma under systemic treatment
2026 · DeTemple, V. K., Chung, S., et al. · Publikationen an der Universität Bielefeld (Universität Bielefeld)
Machine learning‐derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma
2025 · Katrin Schaper‐Gerhardt, Nina Flatt, et al. · Journal of the European Academy of Dermatology and Venereology
PDF
Nachwuchsförderung im Bereich Dermatoonkologie: Das Komitee Next Generation ADO gibt einen Überblick
2024 · Johannes Weil, Noah Zimmermann, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft
PDF
Works count: 16
Citation count: 103
H-index: 6
I10-index: 4
Year
Topic
Type